Upbeat On Injectables, Aurobindo Is Hiking Capacities
Acquisition In Emerging Markets Possible
Executive Summary
Aurobindo expects revenues from injectables to increase to $650m-$700m over the next three years as its Vizag plant gets commissioned in a year’s time. Apart from seeking organic growth, the company is keeping an eye out for acquisitions in emerging markets, though big-ticket M&A is ruled out.